EPZM - エピザイム (Epizyme Inc.) エピザイム

 EPZMのチャート


 EPZMの企業情報

symbol EPZM
会社名 Epizyme Inc. (エピザイム)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エピザイム(Epizyme Inc.)は臨床段階のバイオ医薬品会社である。同社はがん患者向けエピジェネティック治療法の発見・開発・商品化する計画を行う。同社は、がん患者向け新規エピジェネティック治療法の発見・開発に従事する。同社はヒストンメチルトランスフェラーゼ(HMT)として知られる各種酵素小分子阻害剤を開発する。同社は他のクロマチン修飾タンパク質(CMP)の小分子阻害剤を開発する。同社のリード製品候補であるタゼメトスタットは、各種がんにおいて役割を果たす酵素であるゼスト相同体2(EZH2)ヒストンメチルトランスフェラーゼ(HMT)のエンハンサーの選択的阻害剤である。同社は再発性または難治性の非ホジキンリンパ腫(NHL)を有する成人第II相試験及び分子標的腫瘍を有する小児の第I相試験でタゼメトスタットを評価する。同社は日本以外のタゼメトスタットに対する世界的開発・商業化権利を有する。   エピザイムは、米国のバイオ医薬品企業。遺伝によるがん患者向けに個別の治療薬の開発、商品化を行う。ヒストンメチルトランスフェラ―ゼとして知られる酵素の阻害剤作成用に独自の製品プラットフォ―ムを開発。遺伝子変異を持つ急性白血病や、遺伝による非ホジキンリンパ腫および固形腫瘍の治療薬の開発を手掛ける。本社はマサチュ―セッツ州ケンブリッジ。  Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
本社所在地 400 Technology Square Cambridge MA 02139 USA
代表者氏名 David M. Mott デビッド・モット
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-229-5872
設立年月日 39387
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 131人
url www.epizyme.com
nasdaq_url https://www.nasdaq.com/symbol/epzm
adr_tso
EBITDA EBITDA(百万ドル) -139.26100
終値(lastsale) 9.23
時価総額(marketcap) 641865774.42
時価総額 時価総額(百万ドル) 737.47240
売上高 売上高(百万ドル) 12.00000
企業価値(EV) 企業価値(EV)(百万ドル) 521.91640
当期純利益 当期純利益(百万ドル) -136.95600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Epizyme Inc revenues increased 20% to $12M. Net loss increased 4% to $63.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 11% to $54.6M (expense) Stock-based Compensation in SGA increase of 38% to $4M (expense) Other income decrease of 50% to $7K (income).

 EPZMのテクニカル分析


 EPZMのニュース

   The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares  2020/01/17 13:07:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Fortress Biotech (NASDAQ: FBIO ) (announced award of pediatric disease designation for its partner company Cyprium's CUTX-101, which is being evaluated for Menkes disease) Frequency Therapeutics Inc (NASDAQ: FREQ ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mesoblast limited (NASDAQ: MESO ) Minerva Neurosciences Inc (NASDAQ: NERV ) Nantkwest Inc (NASDAQ: NK ) …
   The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance  2020/01/15 13:22:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ): announced an oncology stem cell therapy pact with Astellas Pharma Inc. (OTC: ALPMY ). Applied Therapeutics Inc (NASDAQ: APLT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Calithera Biosciences Inc (NASDAQ: CALA ) Editas Medicine Inc (NASDAQ: EDIT ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (provided 2020 guidance) Hologic, Inc. (NASDAQ: HOLX ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novo Nordisk A/S (NYSE: NVO ) NuVasive, Inc. (NASDAQ: NUVA ) Profound Medical Corp (NASDAQ: PROF ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) Revance Therapeutics Inc (NASDAQ: RVNC ) Syneos Health, Inc. (NASDAQ: SYNH ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Varian Medical Systems, Inc. (NYSE: VAR ) Viela Bio Inc (NASDAQ: VIE ) West Pharmaceutical Services Inc. (NYSE: WST ) XBiotech Inc (NASDAQ: XBIT ) (announced a tender offer to buy up to $420 million worth …
   The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger  2020/01/03 12:55:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Therapeutics Inc (NASDAQ: APLT ) Ascendis Pharma A/S (NASDAQ: ASND ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Epizyme Inc (NASDAQ: EPZM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) INNATE PHARMA S/S ADR (NASDAQ: IPHA )( announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia) The Medicines Company (NASDAQ: MDCO ) Mesoblast limited (NASDAQ: MESO )(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease) Mirati Therapeutics Inc (NASDAQ: MRTX ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) Otonomy Inc (NASDAQ: OTIC ) Syneos Health Inc (NASDAQ: SYNH ) Urovant Sciences Ltd (NASDAQ: UROV ) Veru Inc (NASDAQ: VERU ) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 2) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Evelo Biosciences Inc (NASDAQ: EVLO ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Wave Life Sciences Ltd (NASDAQ: WVE ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) Stocks In Focus Acorda Gains After Hedge Fund Hikes Stake Acorda Therapeutics …
   Epizyme (EPZM) Shares Soar on Lead Candidate's Progress  2019/12/26 15:38:00 Zacks Investment Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
   Epizyme Stock Up on Positive Advisory Votes for Tazemetostat  2019/12/19 09:02:00 Zacks Investment Research
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
   The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance  2020/01/15 13:22:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ): announced an oncology stem cell therapy pact with Astellas Pharma Inc. (OTC: ALPMY ). Applied Therapeutics Inc (NASDAQ: APLT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Calithera Biosciences Inc (NASDAQ: CALA ) Editas Medicine Inc (NASDAQ: EDIT ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (provided 2020 guidance) Hologic, Inc. (NASDAQ: HOLX ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novo Nordisk A/S (NYSE: NVO ) NuVasive, Inc. (NASDAQ: NUVA ) Profound Medical Corp (NASDAQ: PROF ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) Revance Therapeutics Inc (NASDAQ: RVNC ) Syneos Health, Inc. (NASDAQ: SYNH ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Varian Medical Systems, Inc. (NYSE: VAR ) Viela Bio Inc (NASDAQ: VIE ) West Pharmaceutical Services Inc. (NYSE: WST ) XBiotech Inc (NASDAQ: XBIT ) (announced a tender offer to buy up to $420 million worth …
   The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger  2020/01/03 12:55:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Therapeutics Inc (NASDAQ: APLT ) Ascendis Pharma A/S (NASDAQ: ASND ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Epizyme Inc (NASDAQ: EPZM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) INNATE PHARMA S/S ADR (NASDAQ: IPHA )( announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia) The Medicines Company (NASDAQ: MDCO ) Mesoblast limited (NASDAQ: MESO )(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease) Mirati Therapeutics Inc (NASDAQ: MRTX ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) Otonomy Inc (NASDAQ: OTIC ) Syneos Health Inc (NASDAQ: SYNH ) Urovant Sciences Ltd (NASDAQ: UROV ) Veru Inc (NASDAQ: VERU ) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 2) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Evelo Biosciences Inc (NASDAQ: EVLO ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Wave Life Sciences Ltd (NASDAQ: WVE ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) Stocks In Focus Acorda Gains After Hedge Fund Hikes Stake Acorda Therapeutics …
   Epizyme (EPZM) Shares Soar on Lead Candidate's Progress  2019/12/26 15:38:00 Zacks Investment Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
   Epizyme Stock Up on Positive Advisory Votes for Tazemetostat  2019/12/19 09:02:00 Zacks Investment Research
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
   Epizyme's stock jumps on 11-0 vote from FDA adcomm  2019/12/18 19:54:00 MarketWatch
Shares of Epizyme Inc. jumped 16% after a Food and Drug advisory committee voted 11-0 in favor of the regulator approving its experimental cancer therapy….
   The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger  2020/01/03 12:55:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Therapeutics Inc (NASDAQ: APLT ) Ascendis Pharma A/S (NASDAQ: ASND ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Epizyme Inc (NASDAQ: EPZM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) INNATE PHARMA S/S ADR (NASDAQ: IPHA )( announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia) The Medicines Company (NASDAQ: MDCO ) Mesoblast limited (NASDAQ: MESO )(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease) Mirati Therapeutics Inc (NASDAQ: MRTX ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) Otonomy Inc (NASDAQ: OTIC ) Syneos Health Inc (NASDAQ: SYNH ) Urovant Sciences Ltd (NASDAQ: UROV ) Veru Inc (NASDAQ: VERU ) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 2) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Evelo Biosciences Inc (NASDAQ: EVLO ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Wave Life Sciences Ltd (NASDAQ: WVE ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) Stocks In Focus Acorda Gains After Hedge Fund Hikes Stake Acorda Therapeutics …
   Epizyme (EPZM) Shares Soar on Lead Candidate's Progress  2019/12/26 15:38:00 Zacks Investment Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
   Epizyme Stock Up on Positive Advisory Votes for Tazemetostat  2019/12/19 09:02:00 Zacks Investment Research
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
   Epizyme's stock jumps on 11-0 vote from FDA adcomm  2019/12/18 19:54:00 MarketWatch
Shares of Epizyme Inc. jumped 16% after a Food and Drug advisory committee voted 11-0 in favor of the regulator approving its experimental cancer therapy….
   Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma  2019/12/18 19:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エピザイム EPZM Epizyme Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)